Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was... Fedratinib was granted FDA approval on August 16, 2019.
- Mechanism
- Curator reviewed · 5 references
Fedratinib is an inhibitor of Janus Activated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3. JAK2 is highly active in myeloproliferative neoplasms like myelofibrosis. Fedratinib's inhibition of JAK2 inhibits phosphorylation of signal transducer and activator of transcription (STAT) 3 and 5, which prevents cell division and induces apoptosis.
- Primary indication
- Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.Curator reviewed · 4 structured indications
- Formula / weight
- C27H36N6O3S · 524.678 g/mol (avg)
- First approval
- Canada, 2023 · United States, 2019 · European Union, 2021
- Code names
- SAR-302503 · TG-101348
- Brand names
Resolves to
JOOXLOJCABQBSG-UHFFFAOYSA-NSMILESCC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Fedratinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account